NASDAQ:ARAV Aravive (ARAV) Stock Price, News & Analysis $0.04 0.00 (0.00%) As of 05/29/2026 Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsSEC FilingsTrendsBuy This Stock About Aravive Stock (NASDAQ:ARAV) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Aravive alerts:Sign Up Key Stats Today's Range$0.04▼$0.0450-Day Range$0.04▼$0.0452-Week Range$0.04▼$2.46VolumeN/AAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Aravive, Inc. is a clinical-stage biopharmaceutical company focused on the development of innovative therapies that address mechanisms of tumor progression and treatment resistance. The company’s lead product candidate, AVB-500, is a high-affinity soluble receptor decoy designed to neutralize growth arrest-specific 6 (Gas6) and inhibit signaling through the Axl receptor tyrosine kinase. By targeting the Gas6/Axl pathway, Aravive aims to enhance the effectiveness of existing therapies and overcome resistance in oncology indications. AVB-500 is currently being evaluated in multiple Phase 2 clinical studies, including trials in platinum-resistant ovarian cancer and metastatic renal cell carcinoma, where it is administered in combination with standard-of-care treatments. In addition to its oncology programs, Aravive is exploring the role of Gas6/Axl signaling in fibrotic diseases, leveraging translational biomarkers and strategic collaborations to advance its preclinical candidates. The company’s development strategy emphasizes rigorous clinical design and partnerships to expedite the path to potential regulatory approval. Founded in 2015 and headquartered in Houston, Texas, Aravive operates clinical trial sites across North America and Europe. The company is led by Chief Executive Officer R. Joseph Eustace, whose experience in oncology drug development is complemented by a leadership team with deep expertise in translational science, clinical operations and regulatory affairs. Together, Aravive’s management is dedicated to translating novel scientific insights into therapeutic solutions for patients with high unmet needs.AI Generated. May Contain Errors. Read More Receive ARAV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aravive and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ARAV Stock News HeadlinesOut-of-state companies win grants for trials at Houston's MD Anderson Cancer CenterNovember 27, 2024 | bizjournals.comAdial Pharmaceuticals Appoints Vinay Shah To Succeed Joseph Truluck As CFONovember 5, 2024 | markets.businessinsider.comYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.May 30 at 1:00 AM | Profits Run (Ad)Global Automated Cell Culture Market to Exhibit Significant Growth at a CAGR of ~7% by 2030 | DelveInsightOctober 17, 2024 | finance.yahoo.comHouston-based health supplements co. to delist from Nasdaq, dissolveOctober 3, 2024 | bizjournals.comPharmaEssentia Appoints Robert Geller, M.D. as Head of Medical and Shawn Gibbs, J.D. as Head of LegalApril 23, 2024 | finance.yahoo.comDiabetic Kidney Disease Market to Witness Upsurge in Growth at a CAGR of ~6.5% by 2034 | DelveInsightApril 2, 2024 | finance.yahoo.comTelo Genomics Engages US Diagnostics Experts to Power Product Adoption in the USJanuary 30, 2024 | finance.yahoo.comSee More Headlines ARAV Stock Analysis - Frequently Asked Questions How have ARAV shares performed this year? Aravive's stock was trading at $0.0401 on January 1st, 2026. Since then, ARAV stock has increased by 0.0% and is now trading at $0.0401. How were Aravive's earnings last quarter? Aravive, Inc (NASDAQ:ARAV) released its quarterly earnings data on Wednesday, October, 27th. The company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.46) by $0.07. The firm had revenue of $2.41 million for the quarter, compared to the consensus estimate of $2.36 million. When did Aravive IPO? Aravive (ARAV) raised $120 million in an IPO on Thursday, March 20th 2014. The company issued 6,000,000 shares at a price of $19.00-$21.00 per share. How do I buy shares of Aravive? Shares of ARAV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Aravive own? Based on aggregate information from My MarketBeat watchlists, some other companies that Aravive investors own include NVIDIA (NVDA), Broadcom (AVGO), GE Aerospace (GE), Advanced Micro Devices (AMD), CrowdStrike (CRWD) and Meta Platforms (META). Company Calendar Last Earnings10/27/2021Today5/30/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ARAV CIK1513818 Webwww.aravive.com Phone(936) 355-1910FaxN/AEmployees20Year Founded2008Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNo Data BetaN/A Social Links A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.Get This Free Report This page (NASDAQ:ARAV) was last updated on 5/30/2026 by MarketBeat.com Staff. From Our PartnersLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredTrump just signed itA recent policy development is drawing attention from income-focused investors. According to one analyst, c...Investors Alley | SponsoredYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredPH: Do THESE 4 things to your bank account now …In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...Weiss Ratings | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredLegendary Stock Bull Says: “Brace for an Epic Price Crash”For 41 years, Alexander Green urged investors to buy stocks - calling Apple at $1, Netflix at $2, and NVIDIA a...The Oxford Club | SponsoredSkip the Line Opportunity: The SpaceX IPOFormer tech executive and angel investor Jeff Brown - who identified Bitcoin, Tesla, and Nvidia before their h...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aravive, Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Aravive With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
